FindTrial
Sign In

Phase I Study of HAL Formulations Applied to the Cervix in Healthy Volunteers

A Phase I Hexaminolevulinate (HAL) Dose-Finding Study Applying Different Formulations to the Cervix in Healthy Volunteers

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00496171
Enrollment
Unknown
Registered
2007-07-04
Start date
Unknown
Completion date
Unknown
Last updated
2009-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of the study is to determine the most effective formulation of HAL for release of hexaminolevulinate to the cervical epithelium at different doses.

Interventions

None listed

Sponsors

Photocure
Lead SponsorINDUSTRY

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy, pre-menopausal female volunteers

Exclusion criteria

* Acute or chronic disease which could influence the study results

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026